The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

Studies designed, executed, and funded by an Alkermes company.

Filter Publications
Therapeutic Area:
Publication Type:
Showing 10 of 103 results
Sort by date: Descending
May 2023
Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine
CNS Spectrums
AUTHOR(S)

McIntyre RS, Citrome L, Cummings H, Todtenkopf MS, Tan LA, White M, Akerman S

View on PubMed
Review/Commentary
Bipolar Disorder
Schizophrenia
Mar 2023
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
Schizophrenia Bulletin
AUTHOR(S)
Correll CU, Stein E, Graham C, DiPetrillo L, Akerman S, Stanford AD, Jiang Y, Yagoda S, McDonnell D, Hopkinson C
View on PubMed
Clinical
Bipolar Disorder
Schizophrenia
Mar 2023
Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study
The Journal of Clinical Psychiatry
AUTHOR(S)

Kahn RS, Kane JM, Correll CU, Arevalo C, Simmons A, Graham C, Yagoda S, Hu B, McDonnell D

View on PubMed
Clinical
Bipolar Disorder
Schizophrenia
Sep 2022
Olanzapine/samidorphan mitigates weight gain across subgroups of patients known to be at increased risk for weight gain with olanzapine treatment
CNS Spectrums
AUTHOR(S)

Jonathan M Meyer, Adam Simmons, Ying Jiang, Christine Graham, Sergey Yagoda, David McDonnell

View on PubMed
Clinical
Schizophrenia
May 2022
Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals
CNS Spectrums
AUTHOR(S)
Sommi RW, Rege B, Wehr A, Faldu S, Du Y, Weiden PJ
View on PubMed
Review/Commentary
Schizophrenia
Mar 2022
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials
Drug and Alcohol Dependence
AUTHOR(S)
Shulman M, Hu MC, Sullivan MA, Akerman SC, Fratantonio J, Barbieri V, Nunes EV, Bisaga A
View on PubMed
Clinical
Opioid Use Disorder
Mar 2022
Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting
The American Journal on Addictions
AUTHOR(S)
Mannelli P, Douaihy AB, Akerman SC, Legedza A, Fratantonio J, Zavod A, Sullivan MA
View on PubMed
Clinical
Opioid Use Disorder
Feb 2022
Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
Neuropsychopharmacology
AUTHOR(S)

Toledo FGS, Martin WF, Morrow L, Beysen C, Bajorunas D, Jiang Y, Silverman BL, McDonnell D, Namchuk MN, Newcomer JW, Graham C

View on PubMed
Clinical
General
Jan 2022
Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study
Schizophrenia Bulletin Open
AUTHOR(S)

Caligiuri MP, Weiden PJ, Legedza A, Yagoda S, Claxton A

View on PubMed
Clinical
Schizophrenia
Nov 2021
Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone
The American Journal of Drug and Alcohol Abuse
AUTHOR(S)
Mannelli P, Douaihy AB, Zavod A, Legedza A, Akerman SC, Sullivan MA
View on PubMed
Clinical
Opioid Use Disorder